Expertise in
15
conditions

Christophe Massard

Gustave Roussy
Villejuif, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
15
conditions
Gustave Roussy
Villejuif, FR 

Overview

Christophe Massard practices in Villejuif, France. Mr. Massard is highly rated in 15 conditions, according to our data. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Adult Soft Tissue Sarcoma, Orchiectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 361 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drugs: Association atezolizumab, BDB001
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drugs: AMG 596, AMG 404
Study Phase: Phase 1
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drugs: Olaratumab, Pembrolizumab
Study Phase: Phase 1
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drugs: GSK525762, Abiraterone, Enzalutamide, Prednisone
Study Phase: Phase 1
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Enrollment Status: Terminated
Publish Date: June 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

361 Total Publications

New therapies for brain metastases: an update.
New therapies for brain metastases: an update.
Journal: Current opinion in oncology
Published: October 01, 2025

Frequently Asked Questions about Christophe Massard

Is Christophe Massard a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Christophe Massard is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Christophe Massard participate in research or clinical trials?

Yes. Christophe Massard has published 361 articles and abstracts on conditions like Prostate Cancer. You can view a list of Christophe Massard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Massard's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 48 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile